GEN-EXTEND is the open-label extension study for the Phase 3 trial, GENERATION HD1. Whereas GENERATION HD1 is designed to evaluate the effects of Roche’s HD treatment and help decide if it should be made available to patients, GEN-EXTEND evaluates the long-term safety of the same treatment, to understand long-term side effects. Not everyone is able to be a part of this study, only patients who have been involved in the earlier trials in the programme can join an open-label extension.
Estimated Study Completion Date: March 25, 2022